- Home
- MGNX vs NAKA Comparison
MGNX vs NAKA Comparison
Compare MGNX & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGNX | NAKA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 196.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGNX | NAKA |
|---|---|---|
| Price | $4.25 | $4.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $5.00 | $0.75 |
| AVG Volume (30 Days) | ★ 1.4M | 231.0K |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | $1,514.38 |
| Revenue Next Year | $3.19 | $48.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.15 |
| 52 Week High | $5.08 | $16.47 |
Technical Indicators
Market Signals| Indicator | MGNX | NAKA |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 55.74 |
| Support Level | $1.49 | $4.05 |
| Resistance Level | $4.55 | $4.46 |
| Average True Range (ATR) | 0.33 | 0.39 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 12.57 | 76.99 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
About NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.